Anavex Life Sciences Corp (AVXL)

[hnbadger1]

Merck ends trial for oral
Alzheimer's candidate amid
liver toxicity cases
<
• Merck (NYSE:MRK) has terminated a mid-
stage trial for its oral Alzheimer's therapy
MK-1942 amid concerns on liver toxicity, up-
dated data from a federal register on clinical
studies indicated this week.
• The Phase 2a/2b trial evaluated the safety
and efficacy of the oral capsule as an ad-
junctive therapy to treat dementia linked to
mild to moderate Alzheimer's disease.
• In September, the pharma giant discontin-
ed another Phase 2a trial, which evaluated
MK-1942 as an add-on therapy for patients
with treatment-resistant depression who
were on a stable course of antidepressants.
• A spokesperson for Merck (MRK)
told Endpoints News that data from the tri-
als suggested that MK-1942 was linked to
potential liver toxicity as detected by abnor-
mal changes in liver function tests in sev-
eral participants. "No related serious ad.